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The new oral anticoagulants that are currently 
available are dabigatran (Pradaxa, Boehringer Ingelheim), 
a direct thrombin inhibitor, and the activated factor X 
(Xa) inhibitors, apixaban (Eliquis, Pfizer) and 
rivaroxaban (Xarelto, Bayer), with several other agents in 
the pipeline.1-3 These new oral anticoagulants are 
supposed to have a wider therapeutic window than 
warfarin, leading to a lower incidence of major bleeding. 
However, the results of large randomized trials indicate 
that bleeding remains a major concern even with the new 
agents. Studies with rivaroxaban, edoxaban and 
dabigatran showed that these drugs have incidences of 
severe bleeding comparable to those of enoxaparin and 
warfarin. The number of bleeding events is rising due to 
the ageing of the population and the increasing need for 
interventional therapies. The shorter half-life of the new 
agents might facilitate the management of bleeding 
events and the control of anticoagulation during 
interventions or emergency circumstances. If bleeding 
occurs, the lack of specific antidotes limits the therapeutic 
options. Due to the selection bias in the initial 
randomized studies, the absolute bleeding risk might be 
underestimated. This can only be measured after exposure 
of the drugs to larger populations with close post 
marketing surveillance within registries, a strategy that 
would be very helpful in defining the actual bleeding risk 
for the new drug classes. In case of bleeding occurrence, 
supportive care should be sufficient for most patients 
because of the short duration of action of the new agents. 
Some have suggested the use of prothrombin complex 
concentrates as a reversal agent for the new agents, but 
the data are limited.4  
RE-LY demonstrated a higher rate of gastrointestinal 
bleeding with a higher dose of dabigatran, whereas 
ROCKET-AF had a higher rate of major gastrointestinal 
bleeding and epistaxis with rivaroxaban.3 Postmarketing 
surveillance is most critical in further assessing safety in 
the real world. To date, there have been several fatal 
bleeding events reported worldwide with dabigatran (in 
RE-LY, life-threatening bleeds did occur but were 
significantly fewer than with warfarin). Whether these 
events are happening at a higher rate than what was 
expected on the basis of clinical trial data will need to be 
further explored; however, the FDA has issued a re-
assuring statement.5   
One major concern with the new anticoagulants relates 
to kidney function. The new drugs differ from the old 
agents with respect to their elimination through the 
kidneys. These drugs may potentially cause bleeding 
complications in patients with reduced drug excretion due 
to impaired renal function. Dabigatran etexilate and 
rivaroxaban carry the highest risk due to a high degree of 
renal excretion, whereas the risk for apixaban seems 
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lower. Thus, patients with renal insufficiency are at 
increased risk for bleeding complications. This was 
further emphasized in a recent report from the ROCKET-
AF study, whereby patients with AF and moderate renal 
insufficiency receiving rivaroxaban had higher rates of 
stroke and bleeding.6 Specifically, among the 2950 (21%) 
patients with creatinine clearance (CrCl) 30–49 mL/min, 
although they received a reduced dose of rivaroxaban (15 
mg qd instead of 20 mg qd), the principal safety endpoint 
(major and clinically relevant nonmajor bleeding) 
occurred more frequently in those with renal 
insufficiency than in those without. In patients with 
moderate renal insufficiency, rivaroxaban-treated patients 
had more frequent gastrointestinal bleeding (4.1 vs. 2.6%; 
P = 0.02). Fatal bleeding (0.28 vs. 0.74% per 100 patient-
years; P = 0.047) occurred less often with rivaroxaban.   
In a recent study in patients undergoing ablation of 
atrial fibrillation (AF), periprocedural use of dabigatran 
increased the risk of bleeding or thromboembolic 
complications compared with uninterrupted warfarin 
therapy.7 Specifically, in 145 patients receiving 
periprocedural dabigatran, the dose was held on the 
morning of the procedure, while another 145 patients 
received uninterrupted warfarin therapy. Both groups had 
a similar CHADS2 score, left atrial size, and left 
ventricular ejection fraction. A total of 3 thromboembolic 
complications (2.1%) occurred in the dabigatran group 
and none in the warfarin group (p = NS). Dabigatran led 
to a higher major bleeding rate (6% vs 1%; p = 0.019), 
total bleeding rate (14% vs 6%; p = 0.031), and combined 
bleeding and thromboembolic complication rate (16% vs 
6%; p = 0.009) compared with warfarin. Dabigatran use 
was an independent predictor of bleeding or 
thromboembolic complications (odds ratio: 2.76; p = 
0.01) on multivariate regression analysis. The authors 
concluded that in patients undergoing AF ablation, 
periprocedural dabigatran use significantly increases the 
risk of bleeding or thromboembolic complications 
compared with uninterrupted warfarin therapy.  
Although, it was hypothesized that the new 
anticoagulant, apixaban, would be safe and perhaps more 
effective than short-term prophylaxis with enoxaparin for 
prolonging prophylaxis for venous thromboembolism in 
medically ill patients after hospital discharge, this did not 
pan out in the ADOPT trial.8 Specifically, In this placebo-
controlled trial, 4495 acutely ill patients who had 
congestive heart failure or respiratory failure or other 
medical disorders and at least one additional risk factor 
for venous thromboembolism and who were hospitalized 
with an expected stay of at least 3 days were randomized 
to receive oral apixaban (2.5 mg bid) for 30 days 
(n=2211), or subcutaneous enoxaparin (40 mg qd) for 6 to 
14 days (n=2284). Among the participants, 60 (2.71%) in 
the apixaban group and 70 (3.06%) in the enoxaparin 
group met the criteria for the primary efficacy outcome 
(30-day composite of death related to venous 
thromboembolism, pulmonary embolism, symptomatic 
deep-vein thrombosis, or asymptomatic proximal-leg 
deep-vein thrombosis). This translates into a relative risk 
with apixaban of 0.87 (P = NS). By day 30, major 
bleeding had occurred in 0.47% of the patients in the 
apixaban group (15 of 3184 patients) and in 0.19% of the 
patients in the enoxaparin group (6 of 3217 patients) 
(relative risk, 2.58; P = 0.04). The investigators 
concluded that in medically ill patients, an extended 
course of thromboprophylaxis with apixaban was not 
superior to a shorter course with enoxaparin. Apixaban 
was associated with significantly more major bleeding 
events than was enoxaparin. 
A most difficult group of patients are those with atrial 
fibrillation who also have coronary artery disease and are 
submitted to percutaneous coronary intervention and 
stenting, which necessitates triple antithrombotic 
therapy.9 The risk of bleeding in this subset is very high 
with current use of aspirin, clopidogrel and warfarin. 
However, with regards to combining antiplatelet therapy 
with the new oral anticoagulants, there currently exist no 
data.  
Finally, a beacon of light has emerged in the 
management of acute coronary syndromes with the use of 
the newer anticoagulant, bivalirudin.10-13 Bivalirudin is a 
direct thrombin inhibitor, used an as intravenous 
anticoagulant. Its efficacy has been demonstrated in the 
management of patients with non-ST-segment elevation 
acute coronary syndromes (NSTE-ACS) or ST-segment 
elevation myocardial infarction (STEMI). In the ISAR-
REACT 4 trial,12 two antithrombotic regimens were 
compared, the combination of abciximab and 
unfractionated heparin with bivalirudin alone. Bivalidurin 
reduced the risk of bleeding in patients undergoing PCI 
for non–ST-segment elevation myocardial infarction 
without compromising efficacy. Major bleeding occurred 
in 4.6% of the patients in the abciximab group as 
compared with 2.6% in the bivalirudin group (relative 
risk, 1.84; P = 0.02). Similarly, in the Harmonizing 
Outcomes with Revascularization and Stents in Acute 
Myocardial Infarction trial (HORIZONS-AMI), 
bivalirudin was superior to a glycoprotein IIb/IIIa 
inhibitor and heparin in patients undergoing primary PCI 
for ST-segment elevation myocardial infarction.11 
Patients experiencing periprocedural vascular 
complications after percutaneous coronary interventions, 
particularly those with severe bleeding, have an increased 
one-year mortality rate; the use of bivalirudin together 
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with closure devices has been shown to reduce the risk of 
such complications. 14   
Another intravenous direct thrombin inhibitor is 
argatroban.15 The efficacy of argatroban has been 
demonstrated among patients with acute coronary 
syndromes and stroke. However, this drug is currently 
approved by the FDA only for the treatment of patients 
with heparin-induced thrombocytopenia. Although newer 
intravenous direct factor Xa inhibitors have been 
developed, they are still in the testing phase.16 
Fondaparinux is a long-acting indirect factor Xa 
inhibitor,17 but its use was associated with a high rate of 
catheter-related thromboses and thus has not been well 
received.  
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The electrocardiogram (ECG) is crucial in diagnosing 
a variety of cardiovascular conditions in the athlete and 
has been established as an important tool for pre-
participation screening. However, several ECG 
abnormalities may be present even in competitive athletes 
which may increase with age and level of exercise and 
one should discern those which are common and related 
to training from those that are uncommon and training-
unrelated. These issues and the recommendations of 
several authorities for the utility of ECG in this important 
group will be herein reviewed.  
